“…CK2 is an acidophilic PK, i.e., it preferably phosphorylates substrates with clusters of negatively charged amino acid residues flanking the phosphorylatable serine/threonine residue . Therefore, CK2 is inhibited in a protein substrate competitive manner by polyanions, such as heparin, , negatively charged peptides, − and nucleic acids. − The inhibitory potency of these compounds is enhanced with increased number of negatively charged residues, reaching low-nanomolar affinity with higher molecular weight homologues. , Recently, we showed that the potency and selectivity of CK2 inhibition can be remarkably increased by the bisubstrate inhibitor approach (reviewed), i.e., construction of conjugates that simultaneously occupy the binding sites of both the phosphodonor nucleotide and phosphoacceptor protein substrate of the PK. Specifically, the bisubstrate inhibitors designed by us (termed ARCs) targeted to CK2, were constructed by conjugation of ATP-competitive inhibitors, such as TBBz or benzoselenadiazole, with oligo- l -aspartate peptides that mimic the protein substrate recognition (consensus) sequence of CK2. , These fragments were joined via a hydrophobic linker derived from octanoic acid (Oca).…”